Dianthus Therapeutics, Inc. /DE/

Dianthus Therapeutics, Inc.

Biotechnology • Healthcare • New York, NY, United States • DNTH (NCM)

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. The company's lead novel and proprietary monoclonal antibody product candidate includes DNTH103, a human monoclonal immunoglobulin G4 with picomolar that binds the active form of C1s, which is in clinical-stage trials for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

929 999 4055 7 Times Square, New York, NY 10036, United States

Stock Performance (90 Days)

Data through Dec 29, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

First Week of August 2026 Options Trading For Dianthus Therapeutics (DNTH) - Nasdaq
Nasdaq • Dec 19
Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential - Yahoo Finance
Yahoo Finance • Sep 9
Dianthus Therapeutics (NASDAQ:DNTH) CFO Ryan Savitz Sells 20,000 Shares - MarketBeat
MarketBeat • Dec 6
New lupus drug test begins, aiming for simple self-injections every month - Stock Titan
Stock Titan • Dec 23
Leads Biolabs and Dianthus Therapeutics Initiate Phase 1 Trial for LBL-047 (DNTH212), a Bifunctional Fusion Protein Targeting Autoimmune Disorders - Quiver Quantitative
Quiver Quantitative • Dec 23

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Dianthus Therapeutics, Inc. /DE/ had layoffs?
No layoff events have been recorded for Dianthus Therapeutics, Inc. /DE/ in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Dianthus Therapeutics, Inc. /DE/ have?
Dianthus Therapeutics, Inc. /DE/ has approximately 78 employees.
What industry is Dianthus Therapeutics, Inc. /DE/ in?
Dianthus Therapeutics, Inc. /DE/ operates in the Biotechnology industry, within the Healthcare sector.
Is Dianthus Therapeutics, Inc. /DE/ a publicly traded company?
Yes, Dianthus Therapeutics, Inc. /DE/ is publicly traded under the ticker symbol DNTH on the NCM. The company has a market capitalization of approximately $1.78 billion.
Where is Dianthus Therapeutics, Inc. /DE/ headquartered?
Dianthus Therapeutics, Inc. /DE/ is headquartered in New York, NY, United States at 7 Times Square, New York, NY 10036, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.